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Background: Given increased risk of cardiovascular events in asthma we hypothesized that lipoprotein-
associated phospholipase A2 (Lp-PLA2), an enzyme involved in atherosclerosis, is associated with
proinflammatory and prothrombotic blood alterations in this disease.
Methods: In 164 adult asthmatics (63 with severe asthma) we measured plasma Lp-PLA2 activity using
the PLAC test. We determined its relations to inflammation and prothrombotic blood alterations.
Results: In asthma, Lp-PLA2 was inversely related to the age (b ¼ 0.1 [0.18 to 0.02]) and was lower in
women (n ¼ 122 [74%], 205 [182e242] vs. 243 [203e262] nmol/min/ml, p ¼ 0.001). Interestingly, Lp-
PLA2 correlated negatively with the asthma severity score (b ¼ 0.15 [0.23 to 0.07]), being 10.3%
higher in those with non-severe (mild or moderate) asthma (n ¼ 101, 62%) as compared to the severe
disease subtype (224 [191e261] vs. 203 [181e229], p ¼ 0.006 after adjustment for potential con-
founders). Lp-PLA2 activity was positively related to the levels of low-density lipoprotein (b ¼ 0.1 [0.02
e0.18]), triglycerides (b ¼ 0.11 [0.03e0.19]) and glucose (b ¼ 0.1 [0.02e0.18]) and inversely to the tumor
necrosis factor a (b ¼ 0.27 [0.35 to 0.2]), high sensitivity C-reactive protein (b ¼ 0.1 [0.19
to 0.02]) and fibrinogen (b ¼ 0.12 [0.21 to 0.03]), as well as prothrombin (b ¼ 0.16 [0.24
to 0.08]), and parameters describing thrombin generation potential, such as endogenous thrombin
potential (b ¼ 0.14 [0.21 to 0.06]) and peak thrombin generated (b ¼ 0.2 [0.28 to 0.12]).
Conclusions: Elevated Lp-PLA2 activity in non-severe asthmatics suggests increased atherosclerotic risk
in this group. Lower Lp-PLA2 activity accompanied by its inverse relationship to inflammatory or pro-
thrombotic blood biomarkers observed in turn in severe asthmatics might be related to the pathogenesis
of more severe asthma phenotype.
Copyright © 2019, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a member
of phospholipase A2 superfamily. The exact biological function of
this enzyme in humans has not been clarified yet. It is stilliellonian University Medical
s).
ety of Allergology.
ually.
rgology. Production and hosting by Elsecontroversial with seemingly contradictory anti- or pro-
atherogenic functions being proposed.1 Also the evaluation of the
distribution of Lp-PLA2 in the lipid fractions emphasized the dual
role of that enzyme in the vessel inflammatory process. The
circulating Lp-PLA2 enzyme in 20% is related to the high density
lipoprotein (HDL) and contributes to the reduction of atheroscle-
rosis, while in 80% is associated with atherogenic low-density li-
poprotein (LDL).1e3
The secreted isoform of LP-PLA2 was first identified on the basis
of its ability to degrade platelet-activating factor (PAF), pro-
thrombotic and proinflammatory mediator, hence its formed name
was PAF-acetylhydrolase (PAF-AH).1 This enzyme is highlyvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
P. Kuczia et al. / Allergology International 68 (2019) 450e455 451expressed by macrophages, T-lymphocytes, monocytes, and mast
cells in atherosclerotic lesions, particularly within the necrotic core
and fibrotic cap of rupture-prone plaques.4,5 It has been demon-
strated that Lp-PLA2 hydrolyzes oxidized phospholipids and yields
pro-inflammatory and pro-atherogenic products implicated in
endothelial dysfunction with the subsequent atherosclerosis pro-
gression.6,7 Recent studies have shown that increased Lp-PLA2 ac-
tivity or mass is an independent risk marker for cardiovascular
disease (CVD), including coronary heart disease (CHD), and
ischemic stroke.2,5 Moreover, its activity is highly specific for
inflammation associatedwith atherosclerosis, and is not likely to be
falsely elevated from rheumatic diseases, infections or obesity, so it
might be used as an endothelium damage biomarker in diseases
associated with low-grade systemic inflammation.2
Asthma is a chronic inflammatory condition of the airways,
characterized by bronchial reversible obstruction and hyper-
responsiveness.8 Specific patterns of clinical or pathophysiological
features of asthma have been identified, leading to recognition of
asthma phenotypes.9 Recently, epidemiologic studies have
demonstrated that this disease is also associated with an increased
risk of cardiovascular10e13 and thromboembolic events.14e16 The
mechanisms underlying this phenomenon are largely unknown. In
2016 we demonstrated that asthma is related to the enhanced
plasma thrombin formation, impaired clot lysis, and blood platelet
activation,17 which is in line with the study of Sneeboer et al.18 We
also observed that a hypercoagulable state in this disease was
related to increased levels of inflammatory cytokines, including
interleukin (IL)-6 and tumor necrosis factor (TNF)a in circulating
blood.19 Moreover, some prothrombotic plasma alterations have
been shown to lead to the higher exacerbation rate among asth-
matics.20 Interestingly, documented prothrombotic blood abnor-
malities in asthma have been strongly associated with higher
cellular fibronectin (cFN) levels, a marker of vascular injury,21
which was positively correlated with inflammatory parameters,
thus it was not clear whether increased cFN reflects solely endo-
thelial damage or rather low-grade systemic inflammatory state. In
turn, atherosclerosis and asthma may share similar pathophysio-
logical mechanisms including tissue and vascular injury and
inflammation.22,23 Previously, impaired flow mediated dilation of
the brachial artery,24 and increased thickness of the carotid and
femoral intima-media complex25 have been demonstrated in
asthmatic patients, suggesting endothelial dysfunction and sub-
clinical atherosclerosis. To date, only scarce papers have addressed
issue of Lp-PLA2 in asthma. Triggiani et al.26 has found lower Lp-
PLA2 activity in bronchoalveolar lavage fluid of intermittent asth-
matics in comparison to healthy controls. Tsukioka et al.27 and
Stafforini et al.28 have reported lower circulating Lp-PLA2 activity in
stable asthma patients with no clear association to the disease
severity. These observations might contradict our hypothesis about
accelerated atherosclerosis in asthma, however they were per-
formed many years ago, and mainly on Japanese population. Given
complex associations between inflammation, prothrombotic state,
atherosclerosis and endothelial injury in asthma that have been
reported recently,10e13 we sought to evaluate plasma activity of Lp-
PLA2 in asthmatics and assess their relations to prothrombotic
blood alterations and inflammatory markers.
Methods
Subjects studied
We enrolled 164 white adult subjects with clinically stable
asthma (63 [38.4%] patients with severe asthma) recruited at the
outpatient clinic in Cracow, Poland. The patient characteristics,
together with inclusion and exclusion criteria, have been describedin our previous paper in detail.17 Briefly, diagnosis of asthma was
established based on recurrent respiratory symptoms in medical
history, including chest tightness and cough, wheeze, and short-
ness of breath, as well as currently or historically documented post
bronchodilator increase in forced expiratory volume in 1 s (FEV1) of
at least 12% and 200 ml from the baseline.8 All asthma medications
at screening, with the exception of omalizumab, were allowed,
including oral corticosteroids at a daily dose equivalent to8mg of
methylprednisolone. Asthma patients could not be exacerbated
during the 6 months before the enrollment. Moreover, active skin
lesions at enrollment were an exclusion criterion. Severity of
asthma was categorized according to the Global Initiative for
Asthma (GINA) guidelines.8 “Mild” asthma was defined as mild
persistent disease, well-controlled on inhaled short-acting b2-ag-
onists on demand or receiving low daily dose of inhaled cortico-
steroids (ICS) (<250 mg of fluticasone propionate [FP] [dry powder
inhaler] or equivalent). “Moderate” asthma was defined as mild
persistent disease treated with low dose of ICS combined with
long-acting b2-agonists, or medium dose of ICS (250e500 mg of FP
or equivalent). “Severe” asthma was defined as asthma that re-
quires high dose of ICS (>500 mg of FP or equivalent) with long-
acting b2-agonist to prevent it from becoming uncontrolled or
asthma that remains uncontrolled despite this treatment. Non-
severe asthma was defined as mild or moderate asthma, as char-
acterized above. Spirometry was performed using a Jaeger, Master
Screen spirometer in all enrolled subjects according to the Amer-
ican Thoracic Society standards.29 If basal spirometry showed
bronchial obstruction, a bronchial reversibility test with 400 mg of
albuterol was performed and parameters of the second spirometry
were further analyzed.
The study has been approved by the Ethics Committee of the
Jagiellonian University (approval number: KBET/43/B/2014).
Informed consent was obtained from all participants included in
the study and patient anonymity was preserved using methods
approved by the Ethics Committee.
Laboratory investigations
Subjects were fasted overnight and blood was sampled between
08.00 and 10.00 A.M. using minimal stasis. Basic laboratory tests,
including liver enzymes, creatinine level, lipid profile, glucose,
fibrinogen, as well as blood cell and platelet count were analyzed by
routine laboratory techniques. Immunoglobulin E (IgE) and high
sensitivity C-reactive protein (hsCRP) were measured as previously
described.17 Blood samples were drawn into tubes containing so-
dium citrate and serum separation tubes, centrifuged at 2000 g for
20 min at room temperature, within 2 h from sampling. The su-
pernatant was frozen in aliquots and stored at 70 C until further
analysis.
To assess thrombin generation, the Calibrated Automated
Thrombogram (CAT) was used as previously described.17 The
maximum concentration of thrombin generated in this assay is
described as the “thrombin peak”, while the area under the curve of
thrombin formation represents the “endogenous thrombin poten-
tial” (ETP). The CAT assay was obtained using commercially avail-
able reagents (Thrombinoscope, BV, Maastricht, Netherlands) as
described previously.30
Plasma prothrombin and antithrombin activities were
measured using the ACL TOP 500 CTS analyzer and appropriate
reagents (Instrumentation Laboratory, Bedford, MA, USA).17
Commercially available immunoenzymatic assays were used to
analyze TNFa and IL-6,19 P-selectin (all, R&D Systems, Minneapolis,
MN, USA),17 and plasminogen activator inhibitor-1 (PAI-1) (Amer-
ican Diagnostica, Stamford, CT, USA).17 Plasminogen and anti-
plasmin activities were obtained in chromogenic assays (STA
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nostica Stago, Asnieres, France).17
Clot Lysis Time (CLT) was determined to evaluate plasma global
fibrinolytic capacity as previously described.31
The Lp-PLA2 activity in plasma was measured by the PLAC Test
(Diazyme Laboratories, San Diego, CA, USA) according to the
manufacturer's instruction. In this assay Lp-PLA2 hydrolyzes the sn-
2 position of 1-myristoyl-2-(4-nitrophenylsuccinyl) phosphatidyl-
choline (the reaction substrate), producing a colored reaction
product, 4-nitrophenol. The rate of formation of 4-nitrophenol is
assessed spectrophotometrically and the Lp-PLA2 activity is calcu-
lated from the rate of change in absorbance based on a standard
curve fit generated from five Lp-PLA2 calibrators. In 50 healthy
subjects, Lp-PLA2 activity were from 10 to 120 (median 90) nmol/
min/ml (A. Undas unpublished data).
Statistical analysis
Analysis was performed using the STATISTICA 12.5 software
package (StatSoft, Inc, Tulsa, OK, USA). Normality was checked by
the ShapiroeWilk W-test. Continuous variables, all non-normal
distributed, were reported as medians and quartiles. Categorical
variables were given as percentages. Comparisons were made by
the ManneWhitney U test. Categorical variables were compared by
the c2 test. To adjust for potential confounders, including age, body
mass index (BMI), and sex, all non-normal distributed data were
log-transformed and a one-way covariance analysis (ANCOVA) wasTable 1
A summary of clinical and laboratory variables in the subjects studied.
Non-sev
n ¼ 101
Clinical data
Age, years 48 (36e
Male gender, n (%) 25 (25)
Body mass index (kg/m2) 26.5 (24
Current smoking, n (%) 17 (17)
Arterial hypertension, n (%) 33 (33)
Diabetes mellitus, n (%) 6 (6)
Hypercholesterolemia, n (%) 50 (50)
Allergic rhinitis, n (%) 77 (76)
Atopic dermatitis, n (%) 10 (10)
Blood platelets (103/ml) 215 (187
Red blood cells (106/ml) 4.73 (4.4
Hematocrit (%) 41.7 (40
White blood cells (103/ml) 6.35 (5.1
Total cholesterol (mmol/l) 5 (4.3e5
Triglycerides (mmol/l) 1.12 (0.9
Glucose (mmol/l) 5 (4.6e5
Fibrinogen (g/l) 3.6 (2.9e
Prothrombin (%) 109 (99e
Antithrombin (%) 102 (93e
high-sensitivity C-reactive protein (mg/l) 1.21 (0.4
Interleukin-6 (pg/ml) 4.55 (3.5
Tumor necrosis factor a (pg/ml) 4.05 (3.0
P-selectin (ng/ml) 22.38 (1
Endothelial injury
Lipoprotein-associated phospholipase A2 (nmol/min/ml) 224 (191
Thrombin generation and dynamic of thrombin formation
Thrombin peak (nmol/l) 279.6 (2
Endogenous thrombin potential (nmol/l thrombin x min) 1489 (13
Lag-time (min) 2.33 (2e
Time to thrombin peak (min) 5 (4.67e
Fibrinolysis
Clot lysis time (min) 93.4 (71
Plasminogen (%) 105 (94e
Antiplasmin (%) 104 (98e
Plasminogen activator inhibitor-1 (ng/ml) 28.4 (21
Categorical variables are presented as numbers (percentages), continuous variables as m
n, number of subjects.performed, which resulted in an overall p-value. Associations be-
tween continuous variables were calculated by univariate linear
regressions with adjustment for age, sex, and BMI. Independent
determinants of Lp-PLA2 were established in multivariable linear
regressionmodels, built by a forward stepwise selection procedure,
verified by Snedecor's statistics with F > 1 and without residues
autocorrelation (checked by DurbineWatson's statistics). The R2
was used as a measure of the variance.
P-values <0.05 were considered statistically significant.Results
Patient characteristics
Detailed characteristics of the studied patients have been
demonstrated in our previous publication.17 Briefly, we analyzed 63
(38.4%) severe asthmatics, as well as 45 (27.4%) subjects with
moderate and 56 (34.1%) with mild subtype of the disease. Among
all 164 asthma patients 42 (25.6%) were males. The 144 (87.8%)
subjects received inhaled corticosteroids, 26 (15.8%) theophyllin,
124 (75.6%) long-acting b2-agonists, 40 (24.4%)montelukast, and 34
(20.7%) oral corticosteroids.
Patients with severe asthma were older (Table 1). They had also
higher number of white blood cells, as well as increased thrombin
formation parameters as compared to non-severe (mild and mod-
erate) asthmatics.ere asthma
(61.6%)
Severe asthma
n ¼ 63 (38.4%)
p-value
59) 56 (50e64) 0.007
17 (27) 0.75
.1e29.6) 26.7 (23.5e29.7) 0.96
14 (22) 0.39
24 (38) 0.48
7 (11) 0.23
38 (60) 0.18
47 (75) 0.81
8 (13) 0.58
e243) 214 (189e265) 0.33
9e5.05) 4.8 (4.57e5.08) 0.47
e44.2) 42.2 (40.8e44.1) 0.3
8e7.33) 7.13 (5.79e8.64) 0.002
.6) 5.2 (4.5e6.2) 0.08
e1.7) 1.22 (1.01e1.77) 0.3
.3) 4.9 (4.5e5.3) 0.84
3.9) 3.6 (3.2e4.1) 0.21
117) 107 (99e119) 0.88
114) 101 (90e110) 0.2
6e2.35) 1.3 (0.62e3.49) 0.14
8e5.68) 4.55 (3.58e5.98) 0.82
2e4.7) 3.76 (2.91e4.69) 0.72
6.44e33.02) 23.94 (15.04e38) 0.73
e261) 203 (181e229) 0.009
42.8e313) 287.5 (252.8e347) 0.13
04e1620) 1545 (1368e1811) 0.04
2.33) 2.33 (2e2.67) 0.3
6) 5 (4.33e6.33) 0.72
.7e113.5) 102.9 (68.6e124.4) 0.2
118) 107 (96e120) 0.58
116) 101 (95e110) 0.1
.7e39.4) 30.09 (22.02e43.88) 0.33
edian and interquartile range.
Table 2
Independent determinants of lipoprotein-associated phospholipase A2 in severe
asthma.
Severe asthma, n ¼ 63 (38.4%) b 95% CI
Age (years) 0.33 0.42 to 0.24
FEV1 (% of predicted value) 0.3 0.37 to 0.22
Hematocrit (%) 0.26 0.18 to 0.34
Glucose (mmol/l) 0.22 0.14 to 0.29
Prothrombin (%) 0.27 0.34 to 0.2
Antithrombin (%) 0.26 0.16 to 0.34
Tumor necrosis factor a (pg/ml) 0.26 0.35 to 0.17
Plasminogen activator
inhibitor-1 (ng/ml)
0.08 0.004 to 0.16
F ¼ 8.8, R2 ¼ 0.49, p < 0.001
The resulting standardized regression coefficient (b) with 95% confidence intervals
(95%CI) for a factor (independent variable) indicates the increase/decrease in
standard deviations (SDs) of dependent variable, when that particular factor in-
creases with 1 SD and all other variables in the model are unchanged.
n, number of subjects.
Table 3
Independent determinants of lipoprotein-associated phospholipase A2 in non-
severe asthma, defined as a mild or moderate type of the disease.
Non-severe asthma, n ¼ 101 (61.6%) b 95% CI
Hematocrit (%) 0.13 0.05 to 0.2
White blood cells (103/ml) 0.26 0.33 to 0.19
Tumor necrosis factor a (pg/ml) 0.3 0.37 to 0.24
Alanine aminotransferase (IU/l) 0.11 0.04 to 0.17
P-selectin (ng/ml) 0.2 0.13 to 0.26
Triglycerides (mmol/l) 0.11 0.04 to 0.18
Fibrinogen (g/l) 0.09 0.16 to 0.03
Antiplasmin (%) 0.07 0.14 to 0.01
Thrombin peak (nmol/l) 0.1 0.03e0.18
F ¼ 6.7, R2 ¼ 0.24, p < 0.001
The resulting standardized regression coefficient (b) with 95% confidence intervals
(95% CI) for a factor (independent variable) indicates the increase/decrease in
standard deviations (SDs) of dependent variable, when that particular factor in-
creases with 1 SD and all other variables in the model are unchanged.
n, number of subjects.
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In asthma, Lp-PLA2 activity was inversely related to the age
(b ¼ 0.1 [0.18 to 0.02]) and was lower in women than in men
(205 [182e242] vs. 243 [203e262] nmol/min/ml, p ¼ 0.001).
Interestingly, this enzyme activity was inversely related to the
asthma severity score according to the GINA (b ¼ 0.15 [0.23
to 0.07]). Moreover, non-severe (mild and moderate) asthma was
characterized by 10.3% higher Lp-PLA2 activity than severe type of
the disease (p ¼ 0.006 after adjustment for potential confounders)
(Table 1, Fig. 1). We found no difference in Lp-PLA2 activity in
relation to allergic rhinitis, history of atopic dermatitis, and other
internal medicine comorbidities. Also medications used, including
oral corticosteroids, had no impact on Lp-PLA2 activity.
Weak but significant positive correlations were demonstrated
between Lp-PLA2 activity and blood eosinophilia (b ¼ 0.08
[0.01e0.16]), LDL (b ¼ 0.1 [0.02e0.18]), triglycerides (b ¼ 0.11
[0.03e0.19]) and glucose (b ¼ 0.1 [0.02e0.18]) levels. Interestingly,
Lp-PLA2 was inversely related to the inflammatory markers, such as
TNFa (b¼0.27 [0.35 to0.2]), hsCRP (b¼0.1 [0.19 to0.02])
and fibrinogen (b ¼ 0.12 [0.21 to 0.03]), but not to IL-6.
Moreover, we documented negative relationships of Lp-PLA2 ac-
tivity with prothrombin (b ¼ 0.16 [0.24 to 0.08]) and param-
eters describing quantitatively thrombin generation, such as
endogenous thrombin potential (b ¼ 0.14 [0.21 to 0.06]) and
peak thrombin generated (b ¼ 0.2 [0.28 to 0.12]). Conversely,
relation of LP-PLA2 activity to the traits assessing dynamic of
thrombin formation, including time to the beginning of thrombin
formation (lagtime) and time to the thrombin peak, remained
positive (b¼ 0.1 [0.02e0.18] and b¼ 0.15 [0.07e0.23], respectively).
Table 2 shows a multivariable linear regression model with in-
dependent determinants of Lp-PLA2 activity in severe asthma. The
Lp-PLA2 activity was predicted by hematocrit, antithrombin,
glucose and PAI-1 levels, with negative impact of prothrombin and
TNFa (Table 2). Interestingly, in severe asthma Lp-PLA2 activity was
inversely related to the FEV1 (Table 2).
In non-severe asthma the Lp-PLA2 activity was also determined
by hematocrit, followed by triglycerides, P-selectin, and peak
thrombin generated, with negative contribution of TNFa, fibrin-
ogen, white blood cell count, and antiplasmin (Table 3).
Discussion
In the present study we for the first time have shown that Lp-
PLA2 activity in asthma patients depends on asthma severity, being
higher in those with non-severe asthma. Previously publishedFig 1. Lp-PLA2 activity (nmol/min/ml) according to asthma severity.reports have documented lower Lp-PLA2 activity in bron-
choalveolar lavage fluid and blood of asthmatic subjects26e28 in
comparison to healthy controls, with no difference regarding
asthma severity. However, in these studies published in 1990s Lp-
PLA2 activity was determined using different methods based on
radioimmunoassays. Moreover, they were performed mostly on
Japanese population and might mirror the characteristics of this
population.
Clinical relevance of Lp-PLA2 in humans remains unclear. It has
been previously shown that circulating concentrations or activity
of Lp-PLA2 are higher in men than in women, which is in line with
our results.1 Surprisingly, we found that Lp-PLA2 in asthma cor-
relates inversely with age. Regarding laboratory variables, Corsetti
et al.32 studied the association between Lp-PLA2 activity and
clusters of lipid measurements, hemostatic biomarkers, inflam-
matory and glycemic control measures in post-infarction patients.
They found positive relationships of Lp-PLA2 to total cholesterol,
apolipoprotein B, triglycerides and inverse with HDL level. The
fact that Lp-PLA2 in this study was associated with atherogenic
phenotype was not surprising, given that 80% of the enzyme is
bound to apolipoprotein B. In our study we also demonstrated a
weak but positive relationship between Lp-PLA2 and LDL or tri-
glycerides in asthmatics. However, a negative correlation between
Lp-PLA2 activity and inflammatory markers is an interesting
finding, suggesting that asthma inflammation disturbs known
from the CVD group relationship and might decrease Lp-PLA2
activity measurements with a false negative result of PLAC test,
P. Kuczia et al. / Allergology International 68 (2019) 450e455454recommended by the American Heart Association for the CVD risk
stratification in selected subjects.2 That difference with lower
enzyme activity might be also related to the asthmatic medica-
tions, particularly inhaled glucocorticosteroids, which were used
in high doses in all severe asthma patients. Interestingly, Corsetti
et al.32 documented also a nonsignificant trend towards lower Lp-
PLA2 activity at elevated CRP levels.
On the other hand, it has been shown that Lp-PLA2 inactivates
PAF.3 Higher PAF levels have been reported in asthmatics.33,34 PAF
might be responsible for airway hyperactivity or persisting airway
inflammation, including activation of eosinophils and neutrophils
to release granule constituents and to generate superoxide an-
ions.34 Therefore, higher PAF resulting from lower Lp-PLA2 activity
could be related to the further increase in inflammation, explaining
at least partially an inverse correlation of this enzyme activity with
inflammatory markers observed in our study. Henig et al.35 have
shown that intravenous treatment with recombinant human Lp-
PLA2 did not significantly reduce either the early or late asthmatic
response in mild atopic asthma subjects, although recombinant Lp-
PLA2 inhibited airway inflammation and hyperreactivity in a mu-
rine asthma model in mice.36 Our results would suggest that such
therapy might be helpful rather in severe, than mild asthma, since
those subjects are characterized by lower Lp-PLA2 activity. Impor-
tantly, we found no relation between the use of systemic cortico-
steroids and Lp-PLA2 activity, which is in line with previous results
of Stafforini et al.28 Thus, lower Lp-PLA2 activity in severe asth-
matics is likely relating to the pathology of a more severe asthma
phenotype.
It is still unclear however, whether higher plasma activity of Lp-
PLA2 observed in non-severe asthmatics is related to the pathology
of less severe disease course or accelerated atherosclerosis.
Study limitations
The study group was relatively small. Subgroup analysis should
be interpreted with caution. We determined each variable at a
single time point, thus we cannot exclude changes of the variables
analyzed over time. We did not determine other potential modu-
lators of asthma severity, e.g. missense Val279Phe Lp-PLA2 gene
mutation, which as it has been demonstrated in Japanese popula-
tion might be more predominant in more severe asthma pheno-
type.28 We did not study PAF levels, an important substrate for Lp-
PLA2. We also did not determine other phospholipase A2 isozymes.
Statistical associations reported here might not necessarily indicate
cause-effect relationships. In vitro models are needed to elucidate
the role of Lp-PLA2 in asthma pathology, particularly of athero-
sclerosis. Finally, clinical relevance of increased blood Lp-PLA2 ac-
tivity in non-severe asthmatics in relation to asthma course,
progression of bronchial obstruction and vascular outcomes re-
mains to be established.
Conclusions
The Lp-PLA2 activity is higher in subjects with non-severe
asthma, suggesting increased atherosclerotic risk in this group. In
turn, lower Lp-PLA2 activity in severe asthmatics, with inverse
relationship of Lp-PLA2 to inflammatory and prothrombotic blood
biomarkers, might relate to the pathogenesis of more severe
asthma phenotype, although large observational studies are
needed to verify this hypothesis.
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25. Yılmaz M, Bozkurt Yılmaz HE, Şen N, Altın C, Tekin A, Müderrisoglu H. Inves-
tigation of the relationship between asthma and subclinical atherosclerosis by
carotid/femoral intima media and epicardial fat thickness measurement.
J Asthma 2018;55:50e6.
26. Triggiani M, De Marino V, Sofia M, Faraone S, Ambrosio G, Carratù L, et al.
Characterization of platelet-activating factor acetylhydrolase in human bron-
choalveolar lavage. Am J Respir Crit Care Med 1997;156:94e100.
27. Tsukioka K, Matsuzaki M, Nakamata M, Kayahara H, Nakagawa T. Increased
plasma level of platelet-activating factor (PAF) and decreased serum PAF ace-
tylhydrolase (PAFAH) activity in adults with bronchial asthma. J Investig
Allergol Clin Immunol 1996;6:22e9.
28. Stafforini DM, Numao T, Tsodikov A, Vaitkus D, Fukuda T, Watanabe N, et al.
Deficiency of platelet-activating factor acetylhydrolase is a severity factor for
asthma. J Clin Invest 1999;103:989e97.
29. Culver BH, Graham BL, Coates AL, Wanger J, Berry CE, Clarke PK, et al. Rec-
ommendations for a standardized pulmonary function report. An officialAmerican Thoracic Society technical statement. Am J Respir Crit Care Med
2017;196:1463e72.
30. Kremers RMW, Peters TC, Wagenvoord RJ, Hemker HC. The balance of pro- and
anticoagulant processes underlying thrombin generation. J Thromb Haemost
2015;13:437e47.
31. Ząbczyk M, Undas A. Plasma fibrin clot structure and thromboembolism:
clinical implications. Pol Arch Intern Med 2017;127:873e81.
32. Corsetti JP, Rainwater DL, Moss AJ, Zareba W, Sparks CE. High lipoprotein-
associated phospholipase A2 is a risk factor for recurrent coronary events in
postinfarction patients. Clin Chem 2006;52:1331e8.
33. De Boer JD, Majoor CJ, Van't Veer C, Bel EHD, Van Der Poll T. Asthma and
coagulation. Blood 2012;119:3236e44.
34. Kasperska-Zajac A, Brzoza Z, Rogala B. Platelet activating factor as a mediator
and therapeutic approach in bronchial asthma. Inflammation 2008;31:112e20.
35. Henig NR, Aitken ML, Liu MC, Yu AS, Henderson WR. Effect of recombinant
human platelet-activating factor-acetylhydrolase on allergen-induced asth-
matic responses. Am J Respir Crit Care Med 2000;162:523e7.
36. Henderson WR, Lu J, Poole KM, Dietsch GN, Chi EY. Recombinant human
platelet-activating factor- acetylhydrolase inhibits airway inflammation and
hyperreactivity in mouse asthma model. J Immunol 2000;164:3360e7.
